课题基金 / 基金详情

Chemical inhibitors of androgen receptor splice variants lacking the ligand-binding domain as novel agents for castration-resistant prostate cancer

Chemical inhibitors of androgen receptor splice variants lacking the ligand-binding domain as novel agents for castration-resistant prostate cancer
缺乏配体结合域的雄激素受体剪接变体的化学抑制剂作为去势抵抗性前列腺癌的新药
批准号：
212165
负责人：
Wu Jian Hui
金额：
$26.65万
依托单位：
CIUSSS de Centre-Ouest-de-l'Ile-de-Montral-Jewish General
依托单位国家：
加拿大
项目类别：
Operating Grants
财政年份：
2010
资助国家：
加拿大
项目状态：
已结题
起止时间：
2010-09-01 至 2013-09-01
来源：
https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=212165&lang=en
关键词：
Androgen Receptor Antiandrogen Ar Variant Lacking The Lbd Castration-Resistant Prostate Cancer Chemical Optimization Inhibitor Of Ar Variant

项目摘要

项目成果

Wu Jian Hui的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Prostate cancer cell growth is critically dependent on the androgen receptor (AR) signaling. Current treatment strategy for advanced prostate cancer is to reduce level of androgens (via castration) and compete with androgens for binding in the AR ligand-b
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Repurposing of FDA-approved drugs as novel therapeutics for COVID-19
Development of novel pan-inhibitors of the androgen receptor variants as effective therapeutics for castration-resistant prostate cancer
Novel bifunctional antiandrogens that suppress oncogenic activation of the androgen receptor in castration-resistant prostate cancer
海外基金